- Experienced Pharmaceutical Executive 
- Decades of global business development, strategy and biologic drug 
development experience 
- Expertise to drive the next phase of AdAlta's growth

The Board of AdAlta Limited (ASX:1AD), is pleased to announce the appointment 
of experienced global pharmaceutical executive Dr Tim Oldham as Chief Executive 
Officer and Managing Director. Dr Oldham has extensive skills and expertise 
over his career in the industry in strategy and portfolio building, biologic 
therapies development and pipeline commercialisation.

"We are delighted to have someone of Tim's calibre and experience join AdAlta 
as our new Chief Executive Officer," commented Executive Chairman, Paul 
MacLeman. "Tim brings a diverse and international skillset, but his biologics 
and commercialisation expertise will be invaluable as we approach a number of 
important milestones: non human primate pre-clinical results, the commencement 
of phase I human trials for AD-214, and the furthering of late-stage partnering 
discussions for AdAlta's i-body platform. The Board looks forward to working 
with him to continue to progress our strategy around these value-driving 
activities."

Dr Oldham brings more than 20 years' executive leadership experience to AdAlta. 
His expertise spans life sciences strategy and business development, commercial 
and manufacturing operations and alliance management across Europe, Asia and 
Australia, with a particular focus on biologic and cellular therapies and 
pharmaceuticals.

Immediately prior to AdAlta, Dr Oldham was Executive Leader at Tijan Ventures, 
providing strategic planning, capital raising, interim executive management and 
board leadership to transform and grow life sciences companies with a focus in 
the fields of immunotherapy and cell and gene therapy. Previous roles have 
included CEO and Managing Director of Cell Therapies Pty Ltd, a leading Asia 
Pacific contract development and manufacturing organisation for cellular 
therapies, President of Asia Pacific for Hospira, Inc., and a variety of senior 
management roles with Mayne Pharma Ltd in Europe prior to its acquisition by 
Hospira.

These roles encompassed the development and commercialisation of 
pharmaceuticals, devices, biologics and cellular therapies and industry 
advocacy. Dr Oldham was also formerly an engagement manager with global 
strategy consulting firm McKinsey & Co.

Dr Oldham is currently Non-Executive Director of transdermal drug delivery 
company, Acrux Ltd (ASX: ACR) and bispecific antibody company, Immunexus Ltd. 
He is also a member of the Board of BioMelbourne Network Inc.

Dr Oldham will commence in the role of Chief Executive Officer on 14 October 
2019. In accordance with Listing Rule 3.16.4, the key terms of Dr Oldham's 
appointment are attached to this announcement as an appendix.

Notes to Editors

About AdAlta Limited

AdAlta Limited is an Australian based drug development company headquartered in 
Melbourne. The Company is preparing for its phase 1 clinical studies for its 
lead compound AD-214. The clinical program is expected to commence early 2020 
following the release of the current toxicity study data. 

AdAlta's lead i-body candidate, AD-214 is for the treatment of idiopathic 
pulmonary fibrosis (IPF) and other human fibrotic diseases, for which current 
therapies are sub-optimal and there is a high-unmet medical need. AdAlta is 
also in collaborative partnerships to advance the development of its i-body 
pipeline announcing an agreement with UK-based research organisation, 
Excellerate Bioscience on an undisclosed target of commercial interest.

AdAlta has a proprietary technology platform to generate i-bodies, a new class 
of protein therapeutics, with applications as therapeutic drugs to treat 
disease.

Our technology mimics the shape and stability of a crucial antigen-binding 
domain, that was discovered initially in sharks and then developed as a human 
protein. The result is a range of unique compounds, for use in treating serious 
diseases.

The Company also plans to continue further drug discovery and development 
directed towards other drug targets and diseases.

Further information can be found at: www.adalta.com.au.

SOURCE: AdAlta Limited